tiprankstipranks
OrthoPediatrics Corp (DE:2X7)
FRANKFURT:2X7
Germany Market
2X7
OrthoPediatrics
RESEARCH TOOLSreports

OrthoPediatrics (2X7) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

2X7 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
OrthoPediatrics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2X7 Stock 12 Month Forecast

Average Price Target

€21.55
▲(57.29% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for OrthoPediatrics in the last 3 months. The average price target is €21.55 with a high forecast of €29.75 and a low forecast of €14.88. The average price target represents a 57.29% change from the last price of €13.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","30":"€30","15.75":"€15.75","20.5":"€20.5","25.25":"€25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29.75169592,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€29.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.548103294999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€21.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.87584796,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,15.75,20.5,25.25,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,15.580899686153847,16.761799372307692,17.94269905846154,19.123598744615386,20.30449843076923,21.48539811692308,22.666297803076922,23.84719748923077,25.028097175384616,26.20899686153846,27.38989654769231,28.570796233846153,{"y":29.75169592,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.949854099615385,15.499708199230769,16.049562298846155,16.59941639846154,17.149270498076923,17.699124597692308,18.24897869730769,18.798832796923076,19.34868689653846,19.898540996153844,20.44839509576923,20.998249195384613,{"y":21.548103294999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.43660368923077,14.473207378461538,14.509811067692308,14.546414756923078,14.583018446153845,14.619622135384615,14.656225824615385,14.692829513846155,14.729433203076923,14.766036892307692,14.802640581538462,14.83924427076923,{"y":14.87584796,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€29.75Average Price Target€21.55Lowest Price Target€14.88
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on DE:2X7
Ryan Zimmerman
BTIG
BTIG
€21
Buy
53.29%
Upside
Reiterated
06/22/26
OrthoPediatrics (KIDS) Receives a Buy from BTIG
TD Cowen Analyst forecast on DE:2X7
Mathew Blackman
TD Cowen
TD Cowen
€20.13
Buy
46.91%
Upside
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (NASDAQ: KIDS), Gilead Sciences (NASDAQ: GILD) and Savara (NASDAQ: SVRA)
Canaccord Genuity Analyst forecast on DE:2X7
Caitlin Roberts
Canaccord Genuity
Canaccord Genuity
€21.88
Buy
59.68%
Upside
Reiterated
06/02/26
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)
Needham Analyst forecast on DE:2X7
Michael Matson
Needham
Needham
€26.25
Buy
91.62%
Upside
Reiterated
05/01/26
OrthoPediatrics (KIDS) Gets a Buy from Needham
Stifel Nicolaus Analyst forecast on DE:2X7
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
€19.25
Buy
40.52%
Upside
Reiterated
05/01/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Weave Communications (NYSE: WEAV) and OrthoPediatrics (NASDAQ: KIDS)
Lake Street Analyst forecast on DE:2X7
Ben Haynor
Lake Street
Lake Street
€29.75
Buy
117.17%
Upside
Reiterated
05/01/26
Analysts Offer Insights on Healthcare Companies: Option Care Health (NASDAQ: OPCH), Merit Medical Systems (NASDAQ: MMSI) and OrthoPediatrics (NASDAQ: KIDS)
Piper Sandler Analyst forecast on DE:2X7
Matthew O'Brien
Piper Sandler
Piper Sandler
€19.25
Buy
40.52%
Upside
Reiterated
05/01/26
OrthoPediatrics (KIDS) Receives a Buy from Piper Sandler
Citizens JMP Analyst forecast on DE:2X7
David Turkaly
Citizens JMP
Citizens JMP
€30.63→€21.88
Buy
59.68%
Upside
Reiterated
10/10/25
OrthoPediatrics price target lowered to $25 from $35 at Citizens JMPOrthoPediatrics price target lowered to $25 from $35 at Citizens JMP
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on DE:2X7
Ryan Zimmerman
BTIG
BTIG
€21
Buy
53.29%
Upside
Reiterated
06/22/26
OrthoPediatrics (KIDS) Receives a Buy from BTIG
TD Cowen Analyst forecast on DE:2X7
Mathew Blackman
TD Cowen
TD Cowen
€20.13
Buy
46.91%
Upside
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (NASDAQ: KIDS), Gilead Sciences (NASDAQ: GILD) and Savara (NASDAQ: SVRA)
Canaccord Genuity Analyst forecast on DE:2X7
Caitlin Roberts
Canaccord Genuity
Canaccord Genuity
€21.88
Buy
59.68%
Upside
Reiterated
06/02/26
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)
Needham Analyst forecast on DE:2X7
Michael Matson
Needham
Needham
€26.25
Buy
91.62%
Upside
Reiterated
05/01/26
OrthoPediatrics (KIDS) Gets a Buy from Needham
Stifel Nicolaus Analyst forecast on DE:2X7
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
€19.25
Buy
40.52%
Upside
Reiterated
05/01/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Weave Communications (NYSE: WEAV) and OrthoPediatrics (NASDAQ: KIDS)
Lake Street Analyst forecast on DE:2X7
Ben Haynor
Lake Street
Lake Street
€29.75
Buy
117.17%
Upside
Reiterated
05/01/26
Analysts Offer Insights on Healthcare Companies: Option Care Health (NASDAQ: OPCH), Merit Medical Systems (NASDAQ: MMSI) and OrthoPediatrics (NASDAQ: KIDS)
Piper Sandler Analyst forecast on DE:2X7
Matthew O'Brien
Piper Sandler
Piper Sandler
€19.25
Buy
40.52%
Upside
Reiterated
05/01/26
OrthoPediatrics (KIDS) Receives a Buy from Piper Sandler
Citizens JMP Analyst forecast on DE:2X7
David Turkaly
Citizens JMP
Citizens JMP
€30.63→€21.88
Buy
59.68%
Upside
Reiterated
10/10/25
OrthoPediatrics price target lowered to $25 from $35 at Citizens JMPOrthoPediatrics price target lowered to $25 from $35 at Citizens JMP
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering OrthoPediatrics

3 Months
Matthew O'BrienPiper Sandler
Success Rate
10/18 ratings generated profit
56%
Average Return
+1.47%
Copying Matthew O'Brien's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +1.47% per trade.
1 Year
Rick WiseStifel Nicolaus
Success Rate
7/24 ratings generated profit
29%
Average Return
-12.25%
Copying Rick Wise's trades and holding each position for 1 Year would result in 29.17% of your transactions generating a profit, with an average return of -12.25% per trade.
2 Years
Ryan ZimmermanBTIG
Success Rate
4/26 ratings generated profit
15%
Average Return
-26.65%
Copying Ryan Zimmerman's trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -26.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2X7 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
3
5
7
7
Buy
11
9
5
2
5
Hold
1
2
1
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
14
11
11
13
In the current month, 2X7 has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 2X7 average Analyst price target in the past 3 months is 21.55.
Each month's total comprises the sum of three months' worth of ratings.

2X7 Financial Forecast

2X7 Earnings Forecast

Next quarter’s earnings estimate for 2X7 is -€0.26 with a range of -€0.35 to -€0.16. The previous quarter’s EPS was -€0.39. 2X7 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2X7 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2X7 is -€0.26 with a range of -€0.35 to -€0.16. The previous quarter’s EPS was -€0.39. 2X7 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2X7 has Performed in-line its overall industry.

2X7 Sales Forecast

Next quarter’s sales forecast for 2X7 is €59.12M with a range of €58.84M to €59.61M. The previous quarter’s sales results were €51.44M. 2X7 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2X7 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2X7 is €59.12M with a range of €58.84M to €59.61M. The previous quarter’s sales results were €51.44M. 2X7 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2X7 has Performed in-line its overall industry.

2X7 Stock Forecast FAQ

What is DE:2X7’s average 12-month price target, according to analysts?
Based on analyst ratings, OrthoPediatrics Corp’s 12-month average price target is 21.55.
    What is DE:2X7’s upside potential, based on the analysts’ average price target?
    OrthoPediatrics Corp has 57.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OrthoPediatrics Corp a Buy, Sell or Hold?
          OrthoPediatrics Corp has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is OrthoPediatrics Corp’s share price target?
            The average share price target for OrthoPediatrics Corp is 21.55. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €29.75 ,and the lowest forecast is €14.88. The average share price target represents 57.29% Increase from the current price of €13.7.
              What do analysts say about OrthoPediatrics Corp?
              OrthoPediatrics Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of OrthoPediatrics Corp?
                To buy shares of DE:2X7, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.